Functional imaging of neuroendocrine tumours with PET

Pituitary

Volumn 9, Issue 3, 2006, Pages 237-242

  Mottaghy, Felix M ^a   Reske, Sven N ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Molecular imaging; Neuroendocrine tumour; PET

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 3 HYDROXYEPHEDRINE; 5 HYDROXYTRYPTOPHAN; 6 FLUORODOPAMINE; BIOGENIC AMINE; CARBON 11; DOPA; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; METOMIDATE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE;

COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DOSIMETRY; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HORMONE SYNTHESIS; HUMAN; INDIVIDUALIZATION; ISOTOPE LABELING; MEDICAL LITERATURE; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PARAGANGLIOMA; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION;

ANIMALS; BIOGENIC AMINES; ENZYME INHIBITORS; FLUORODEOXYGLUCOSE F18; HUMANS; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SOMATOSTATIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33750975924     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-006-0269-y     Document Type: Review

References (65)

1. Pearse AG (1968) Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimobranchial C cells and calcitonin. Proc R Soc Lond B Biol Sci 170:71-80
2. Pearse AG (1980) The APUD concept and hormone production. Clin Endocrinol Metab 9:211-222
3. Atkins FL, Beaven MA, Keiser HR (1973) Dopa decarboxylase in medullary carcinoma of the thyroid. N Engl J Med 289:545-548
4. Baylin SB, Hsu TH, Stevens SA, Kallman CH, Trump DL, Beaven MA (1979) The effects of L-dopa on in vitro and in vivo calcitonin release from medullary thyroid carcinoma. J Clin Endocrinol Metab 48:408-414
5. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427
6. Patel RC, Kumar U, Lamb DC, Eid JS, Rocheville M, Grant M et al (2002) Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci USA 99:3294-3299
7. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB (1995) The somatostatin receptor family. Life Sci 57:1249-1265
8. Patel YC, Srikant CB (1994) Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 135:2814-2817
9. Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20:157-198
10. Stroh T, Jackson AC, Dal Farra C, Schonbrunn A, Vincent JP, Beaudet A (2000) Receptor-mediated internalization of somatostatin in rat cortical and hippocampal neurons. Synapse 38:177-186.
11. Williams ED, Sandler M (1963) The classification of carcinoid tum ours. Lancet 1:238-239
12. Solcia E, Klöppel G, Sobin L (2000) Histological typing of endocrine tumours. Berlin: Springer
13. Pacak K, Eisenhofer G, Goldstein DS (2004) Functional imaging of endocrine tumors: Role of positron emission tomography. Endocr Rev 25:568-580
14. Lamberts SW, Bakker WH, Reubi JC, Krenning EP (1990) Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 323:1246-1249
15. Bergstrom M, Bonasera TA, Lu L, Bergstrom E, Backlin C, Juhlin C et al (1998) In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med 39:982-989
16. Brown RS, Wahl RL (1993) Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 72:2979-2985
17. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC (1999) Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 212:35-41
18. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G (1998) Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25:79-83
19. Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH, Hor G (1998) Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: Comparison with the expression of the Ki-67 antigen. Nucl Med Commun 19:641-647
20. Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F et al (1998) Neuroendocrine tumor imaging: Can 18 F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 22:588-592
21. Belhocine T, Foidart J, Rigo P, Najjar F, Thiry A, Quatresooz P et al (2002) Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun 23:727-734
22. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P et al (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: Results of a multicentre study. Eur J Nucl Med 28:1671-1676
23. Szakall S Jr, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I et al (2002) 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43:66-71
24. Garnett S, Firnau G, Nahmias C, Chirakal R (1983) Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res 280:169-171
25. Reibring L, Agren H, Hartvig P, Tedroff J, Lundqvist H, Bjurling P et al (1992) Uptake and utilization of [beta-11C]5-hydroxytryptophan in human brain studied by positron emission tomography. Psychiatry Res 45:215-225
26. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS (2001) 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38:6-8
27. Eriksson B, Bergstrom M, Lilja A, Ahlstrom H, Langstrom B, Oberg K (1993) Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta Oncol 32: 189-196
28. Orlefors H, Sundin A, Ahlstrom H, Bjurling P, Bergstrom M, Lilja A et al (1998) Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J Clin Oncol 16:2534-2541
29. Sundin A, Eriksson B, Bergstrom M, Bjurling P, Lindner KJ, Oberg K et al (2000) Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography. Nucl Med Biol 27:33-41
30. Orlefors H, Sundin A, Lu L, Oberg K, Langstrom B, Eriksson B et al (2006) Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging 33:60-65
31. Eriksson B, Bergstrom M, Orlefors H, Sundin A, Oberg K, Langstrom B (2000) Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med 44:68-76
32. Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B et al (2005) Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90:3392-3400
33. Bergstrom M, Eriksson B, Oberg K, Sundin A, Ahlstrom H, Lindner KJ et al (1996) In vivo demonstration of enzyme activity in endocrine pancreatic tumors: Decarboxylation of carbon-11-DOPA to carbon-11-dopamine. J Nucl Med 37: 32-37
34. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H et al (2001) Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 220: 373-380
35. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E (2001) 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64-71
36. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I et al (2002) Pheochromocytomas: Detection with 18F DOPA whole body PET-initial results. Radiology 222:507-512
37. Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E et al (2003) 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 30:689-694
38. Ilias I, Yu J, Carrasquillo JA, Chen CC, Eisenhofer G, Whatley M et al (2003) Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 88:4083-4087
39. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L et al (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1: 242-244
40. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH et al (2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36:147-156
41. Guhlke S, Wester HJ, Bruns C, Stocklin G (1994) (2-[18F]fluoropropionyl-(D)phe1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: Synthesis, radiolabeling, in vitro validation and biodistribution in mice. Nucl Med Biol 21:819-825
42. Wester HJ, Brockmann J, Rosch F, Wutz W, Herzog H, Smith-Jones P et al (1997) PET-pharmacokinetics of 18F-octreotide: A comparison with 67Ga-DFO- and 86Y-DTPA-octreotide. Nucl Med Biol 24:275-286
43. Rosch F, Herzog H, Stolz B, Brockmann J, Kohle M, Muhlensiepen H et al (1999) Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue. Eur J Nucl Med 26:358-366
44. Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Wang J, Anderson CJ (1999) Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: Evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem 42: 1341-1347
45. Lewis JS, Srinivasan A, Schmidt MA, Anderson CJ (1999) In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake. Nucl Med Biol 26:267-273
46. Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA et al (2001) 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 42:213-221
47. Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J et al (2001) PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: First results in patients with meningiomas. J Nucl Med 42:1053-1056
48. Meisetschlager G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M et al (2006) Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: Biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J Nucl Med 47:566-573
49. Schottelius M, Poethko T, Herz M, Reubi JC, Kessler H, Schwaiger M et al (2004) First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res 10:3593-3606
50. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L et al (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: Preliminary data. Eur J Nucl Med 28:1751-1757
51. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U (2003) Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5:42-48
52. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J et al (2005) Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 46:763-769
53. Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A et al (2006) Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys 65:222-227
54. Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H et al (2005) 68Ga-DOTANOC: A first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 32:724
55. Macke HR, Smith-Jones P, Maina T, Stolz B, Albert R, Bruns C et al (1993) New octreotide derivatives for in vivo targeting of somatostatin receptor-positive tumors for single photon emission computed tomography (SPECT) and positron emission tomography (PET). Horm Metab Res Suppl 27:12-17
56. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS et al (1992) PET scanning with hydroxyephedrine: An approach to the localization of pheochromocytoma. J Nucl Med 33:1125-1131
57. Trampal C, Engler H, Juhlin C, Bergstrom M, Langstrom B (2004) Pheochromocytomas: Detection with 11C hydroxyephedrine PET. Radiology 230:423-428
58. Mann GN, Link JM, Pham P, Pickett CA, Byrd DR, Kinahan PE et al (2006) [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol 13:187-197
59. Bergstrom M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerstrom G et al (2000) PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. J Nucl Med 41:275-282
60. Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, Langsjo J et al (2004) Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. J Nucl Med 45: 972-979
61. Hennings J, Lindhe O, Bergstrom M, Langstrom B, Sundin A, Hellman P (2006) [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 91:1410-1414
62. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R et al (2000) A combined PET/CT scanner for clinical oncology. J Nucl Med 41:1369-1379
63. von Schulthess GK, Steinert HC, Hany TF (2006) Integrated PET/CT: current applications and future directions. Radiology 238:405-422
64. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716
65. Glatting G, Landmann M, Wunderlich A, Kull T, Mottaghy FM, Reske SN (2006) Internal radionuclide therapy: A software for treatment planning using tomographic data. Nuklearmedizin 45:iN press